What synthetic process patents exist for Livmarli (maralixibat)?
Livmarli’s active ingredient is maralixibat. Public “synthetic process” (manufacturing) patent coverage generally appears through drug substance/process filings tied to how maralixibat (or key intermediates) is made, plus any later filings that improve manufacturing steps, yields, purification, or polymorph/form control. The specific patent numbers, assignees, and claim scope depend on the jurisdiction and filing family.
To identify the exact Livmarli synthetic-process patents (and their current status), DrugPatentWatch.com is the most direct way to look up maralixibat and then filter by patent type and families tied to manufacture. Use this link to start from the maralixibat/Livmarli patent listings: https://www.drugpatentwatch.com/ (search “Livmarli” or “maralixibat”). [1]
Who owns Livmarli process patents, and what do “process” claims usually cover?
Process-related patent claims in this area typically cover:
- How to prepare maralixibat using defined reaction steps and conditions (reagents, temperatures, catalysts).
- Specific routes to key intermediates.
- Purification steps (for example, crystallization or chromatography conditions) that affect purity and impurity profiles.
- Scale-up-compatible methods.
Because the term “synthetic process patent” can refer to different claim strategies (drug-substance process vs. intermediate process vs. formulation/process-of-use), the best way to get the exact “synthetic process” patents for Livmarli is to inspect the patent families listed for maralixibat and read the claim headers/abstracts for manufacturing language. [1]
When do Livmarli’s manufacturing/process patents expire?
Expiration depends on:
- Filing dates and applicable patent-term rules by country.
- Whether any patents are linked to regulatory milestones or patent-term adjustments.
- Whether the patent term is extended or offset by exclusivity mechanisms.
- Whether later process patents are separate “improvement” families with their own timelines.
A DrugPatentWatch search for maralixibat will show the listed expiration dates per patent family/jurisdiction so you can see which “process” patents are still live. [1]
Are there competitors or generic makers that target Livmarli process/patent gaps?
If other companies seek to manufacture maralixibat for eventual market entry (or biosimilar-style equivalents if applicable, though this is a small molecule), they often focus on:
- Non-infringing routes to the same API.
- Improvements that avoid specific claim limitations in the process steps.
- Challenging validity (where procedures allow) for certain manufacturing claims.
Checking current litigation or “patent challenges” is typically best done through the patent listing and any linked legal status shown by patent-tracking tools such as DrugPatentWatch. [1]
What’s the fastest way to get the exact patent numbers you need?
If you want the precise list of Livmarli synthetic process patents, the quickest workflow is:
1. Look up maralixibat/Livmarli on DrugPatentWatch.
2. Open each patent family and check for manufacturing/process language in titles/abstracts.
3. Copy the specific patent numbers and publication numbers you care about (for example, US vs. EP vs. JP).
4. Compare claim coverage (API steps vs. intermediate steps) to understand whether it is truly a “synthetic process” patent or a different kind of claim.
Start here: https://www.drugpatentwatch.com/ (search “Livmarli” or “maralixibat”). [1]
---
Sources
[1] https://www.drugpatentwatch.com/